Analysts See $1.39 EPS for Quest Diagnostics (DGX); Inogen (INGN)’s Sentiment Is 1.2

December 24, 2017 - By Henry Gaston

Inogen, Inc., a medical technology company, primarily develops, makes, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company has market cap of $2.52 billion. The companyÂ’s oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It has a 98.25 P/E ratio. It offers Inogen One systems, which are portable devices that concentrate the air around the patients to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories.

Analysts expect Quest Diagnostics Incorporated (NYSE:DGX) to report $1.39 EPS on January, 25.They anticipate $0.08 EPS change or 6.11% from last quarter’s $1.31 EPS. DGX’s profit would be $189.45 million giving it 17.85 P/E if the $1.39 EPS is correct. After having $1.39 EPS previously, Quest Diagnostics Incorporated’s analysts see 0.00% EPS growth. The stock increased 0.09% or $0.09 during the last trading session, reaching $99.24. About 464,987 shares traded. Quest Diagnostics Incorporated (NYSE:DGX) has risen 39.04% since December 24, 2016 and is uptrending. It has outperformed by 22.34% the S&P500.

Analysts await Inogen, Inc. (NASDAQ:INGN) to report earnings on February, 27. They expect $0.21 earnings per share, down 16.00% or $0.04 from last year’s $0.25 per share. INGN’s profit will be $4.38 million for 143.98 P/E if the $0.21 EPS becomes a reality. After $0.33 actual earnings per share reported by Inogen, Inc. for the previous quarter, Wall Street now forecasts -36.36% negative EPS growth.

The stock increased 0.42% or $0.51 during the last trading session, reaching $120.94. About 101,830 shares traded. Inogen, Inc. (INGN) has risen 88.09% since December 24, 2016 and is uptrending. It has outperformed by 71.39% the S&P500.

Brown Capital Management Llc holds 2.57% of its portfolio in Inogen, Inc. for 2.22 million shares. Tirschwell & Loewy Inc owns 165,955 shares or 2.39% of their US portfolio. Moreover, Oberweis Asset Management Inc has 1.55% invested in the company for 58,420 shares. The New York-based Atika Capital Management Llc has invested 1.34% in the stock. Cortina Asset Management Llc, a Wisconsin-based fund reported 308,756 shares.

Among 20 analysts covering Quest Diagnostics (NYSE:DGX), 7 have Buy rating, 2 Sell and 11 Hold. Therefore 35% are positive. Quest Diagnostics had 56 analyst reports since August 4, 2015 according to SRatingsIntel. FBR Capital maintained the shares of DGX in report on Wednesday, April 12 with “Outperform” rating. The rating was maintained by Canaccord Genuity with “Buy” on Monday, September 11. SunTrust maintained Quest Diagnostics Incorporated (NYSE:DGX) rating on Friday, October 13. SunTrust has “Hold” rating and $105.0 target. The stock of Quest Diagnostics Incorporated (NYSE:DGX) earned “Hold” rating by Credit Suisse on Thursday, July 13. Piper Jaffray maintained it with “Hold” rating and $103.0 target in Thursday, October 19 report. The rating was maintained by Piper Jaffray with “Hold” on Wednesday, October 11. The stock of Quest Diagnostics Incorporated (NYSE:DGX) earned “Outperform” rating by Raymond James on Friday, April 21. The rating was upgraded by Wells Fargo to “Market Perform” on Friday, October 16. On Monday, December 12 the stock rating was upgraded by Goldman Sachs to “Buy”. Mizuho upgraded the shares of DGX in report on Tuesday, January 3 to “Buy” rating.

Since August 4, 2017, it had 0 insider buys, and 5 insider sales for $11.54 million activity. 296 shares were sold by LEIDEN JEFFREY M, worth $31,571. RUSCKOWSKI STEPHEN H sold 59,235 shares worth $6.41M. $4.42 million worth of Quest Diagnostics Incorporated (NYSE:DGX) was sold by STANZIONE DANIEL on Monday, September 11.

Investors sentiment decreased to 0.98 in Q3 2017. Its down 0.01, from 0.99 in 2017Q2. It turned negative, as 51 investors sold Quest Diagnostics Incorporated shares while 184 reduced holdings. 57 funds opened positions while 173 raised stakes. 116.90 million shares or 2.64% more from 113.89 million shares in 2017Q2 were reported. Oregon Employees Retirement Fund reported 45,076 shares. Acadian Asset Lc accumulated 0.59% or 1.41 million shares. Hall Laurie J Trustee holds 0.02% or 300 shares in its portfolio. Dupont Mngmt invested 0.04% in Quest Diagnostics Incorporated (NYSE:DGX). Td Asset Management has invested 0.01% in Quest Diagnostics Incorporated (NYSE:DGX). Old Mutual Customised Solutions (Proprietary) Limited has invested 0.09% in Quest Diagnostics Incorporated (NYSE:DGX). Weybosset & Mgmt Ltd Com accumulated 37,277 shares or 2.32% of the stock. 6,700 are held by Caxton Assocs Lp. Laurion Capital Mngmt Lp reported 73,600 shares or 0.03% of all its holdings. Rampart Management Co Ltd Co stated it has 1,876 shares or 0.06% of all its holdings. Nomura Asset Mgmt Ltd reported 0.02% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Chicago Equity Prtn Lc holds 2,355 shares or 0.01% of its portfolio. Cibc Ww Corp reported 20,998 shares. Palo Cap reported 10,636 shares. Dreman Value Mngmt L L C owns 12,512 shares.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $13.53 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 20.81 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.